SPY240725C549000
- 0.01
- -0.38-97.44%
SPDR S&P 500 ETF Newsroom
Fed, FDIC, OCC Seek More Information From Banks on Bank-fintech Arrangements
Dow Leads Indexes Higher; GDP Beats Expectations
Express News | Manhattan DA Says Trump's Hush Money Conviction Should Stand; SCOTUS Ruling Has No Impact On Case
What's Going On With Tech Giant Meta's Stock Today?
Alphabet Stock Falls As OpenAI Plans 'SearchGPT': What Investors Need To Know
Ford Options Volume Jump as Stock Heads for Worst Slump Since 2008
Is the weight loss drug field about to change? Viking Therapeutics surged nearly 40% intraday, causing eli lilly and co's market cap to shrink by $120 billion.
After communicating with regulatory institution FDA, USA's Viking Therapeutics unexpectedly made progress in advancing weight loss drug VK2735 to phase III clinical trials, which may lead to an advance of its launch time by one year. This drug is expected to be injected once a month, which is more convenient than the same magical medicine from Eli Lilly and Novo Nordisk. The oral version of VK2735 will start phase II trials in the fourth quarter of this year. Coupled with the bullish news from Swiss pharmaceutical company Roche in the same field, Eli Lilly's stock has fallen by 14% in eight trading days, the worst since 2020, reducing its market cap by more than 120 billion USD from its peak.
Express News | Trump Leads Harris 48%-46% Among Registered Voters, NYT/Sienna College Poll Finds; Margin Of Error Is 3.3 Points
OpenAI Begins Testing AI-powered Search; GOOG Slips 2%
ServiceNow CEO Highlights Long-Running Partnership With Nvidia, 'Lightening Fast' AI Models That Run Inexpensively: 'We're The Unicorn'
Macquarie Downgrades Warner Bros. Discovery on Loss of NBA Rights to Amazon
Barclays Creates Growth-quality Basket for Targeted Approach to Small-cap Stocks
Apple Rises as Baird Bumps Price Target on AI Opportunity
Intel Taps Micron Leader To Strengthen AI Chip Strategy
Amazon.com Analyst Ratings
Viking Therapeutics Stock Surges 31% As Company Advances Weight Loss Drug To Late-Stage Trial
10 Consumer Discretionary Stocks Whale Activity In Today's Session
10 Information Technology Stocks Whale Activity In Today's Session
Essilor Luxottica CEO Says Sees Supreme As A Communication Platform, A Direct Channel To An Audience Difficult To Reach; Relationship With Meta Is Really Strong, We Believe The Partnership Will Last Very Long; He Is Informed Of Meta's Intention To...
Benchmark Reiterates Hold on Meta Platforms